8 results about "Phage therapy" patented technology

The invention relates to the technical field of biological medicine, in particular to a composition for blocking formation of phage treatment tolerance and application of the composition. The composition comprises a folium ilicis purpurea ethyl acetate extraction active component and a clostridium perfringens specific bacteriophage, the folium ilicis purpurea ethyl acetate extraction active component is prepared from the following components in percentage by mass: 8 to 15 percent of protocatechuic acid and 5 to 10 percent of ethyl gallate, and the mass ratio of the protocatechuic acid to the ethyl gallate is (1.5 to 1) to (2.5 to 1); the clostridium perfringens specific bacteriophage is a virulent bacteriophage capable of specifically cracking a clostridium perfringens NetB toxin positive strain. According to the invention, the shallow thought that the existing compounding technology only pursues synergistic sterilization is subverted, and a deep synergistic mode of bacteriophage splitting attack and folium ilicis purpurea component disintegration bacterial defense program is proposed and verified for the first time. And the formation of tolerance is fundamentally blocked, so that a more thorough and more lasting treatment effect is realized, and the comprehensive production performance of animals is accidentally and greatly improved on the basis of the treatment effect.

The present invention relates to phage therapy. More specifically, the present invention relates to novel phages with high specificity against Escherichia coli strains, their manufacture, components thereof, compositions comprising them and their use in phage therapy.

The present application belongs to the technical field of microbial prevention and treatment, and particularly relates to a mycobacterium phage and application thereof. Specifically, the present application successfully screens a mycobacterium phage MP1 capable of precisely targeting and killing mycobacterium marinum, which can precisely target and kill specific mycobacterium marinum without causing adverse effects on normal flora. This feature enables the phage therapy to avoid the adverse reactions and flora imbalance problems caused by antibiotic treatment when treating drug-resistant mycobacterium marinum. Meanwhile, the above-mentioned mycobacterium phage MP1 is obtained from nature and is easy to be industrialized, and a drug or environmental disinfectant prepared from the above-mentioned phage not only can reduce the cost, but also has the advantages of green environmental protection and the like, and therefore has good practical application value.

The application belongs to the field of nanomaterials and biomedicine, and provides a X03 phage-cerium oxide nanoscale enzyme composite treatment platform based on chemical cross-linking of polyethylene glycol, a synergistic treatment platform integrating bactericidal and detoxification functions, namely X03@CeO2, is constructed by covalently coupling phage X03 targeting pseudomonas aeruginosa and CeO2 nanoscale enzyme with phosphatase activity, which solves the problem that antibiotic and phage therapy exacerbate systemic inflammatory storm due to massive release of lipopolysaccharide caused by bacterial lysis when killing multiple drug-resistant gram-negative bacteria. In vitro and in vivo experiments show that the complex can efficiently remove bacteria and biofilm, simultaneously degrade released LPS, significantly inhibit the production of inflammatory factors, active oxygen burst and TLR4 pathway activation, greatly improve the survival rate in a lethal sepsis mouse model and reverse multiple organ damage. The application is suitable for treating sepsis caused by drug-resistant gram-negative bacteria.

To provide a method for treating implantable device infections. [Solution] The present invention relates to the field of phage therapy, and more particularly to providing phage-based compositions and methods for treating or preventing infections associated with implantable devices. The compositions may be administered directly to the infection site of the device, as a single dose and / or by other means as needed, potentially avoiding the need to replace the implantable device. The method may include (a) obtaining a biological sample from the subject; (b) culturing bacteria present in the biological sample; and (c) inoculating the cultured bacteria with a phage to lyse them.

The invention relates to the technical field of microorganisms, in particular to a bacteriophage compound preparation for vibrio harveyi and application. The compound preparation comprises a vibrio harveyi bacteriophage RDP-VB25018 with the preservation number of CGMCC (China General Microbiological Culture Collection Center) No. 46671 and a vibrio harveyi bacteriophage RDP-VB25018R with the preservation number of CGMCC No. 46672. The compound preparation can effectively overcome the problem that bacteria easily generate resistance in bacteriophage treatment, has a high-efficiency synergistic lysis effect on original strains and resistant strains of Vibrio harveyi, has a lysis spectrum width of 84%, is far superior to that of a single bacteriophage, and has a good application prospect. And one or more of vibrio orientalis, vibrio harveyi, vibrio cholerae, vibrio canbainii, vibrio Ewana, vibrio alginolyticus and vibrio parahaemolyticus can be cracked. Animal experiments show that the compound preparation can obviously reduce the death rate of infected prawns from 85% or above to about 11%, and pathogenic bacteria in tissues are thoroughly removed. The invention provides an efficient and safe solution for green prevention and control of aquatic vibriosis.

This invention provides a thermoresistant Bacillus pumilus P2-7 strain and its application in the prevention and control of diseases in shrimp farming, belonging to the field of bioengineering technology. The thermoresistant Bacillus pumilus P2-7 strain provided by this invention was deposited at the Guangdong Provincial Microbial Culture Collection Center on November 4, 2024, with accession number GDMCC NO.65408. This strain differs from traditional antibacterial Bacillus strains in its antagonistic mechanism; it does not secrete metabolites with antibacterial activity, but rather exerts its effects through phage therapy. It can significantly eliminate / inhibit pathogenic bacteria in water and effectively control Shevax disease in shrimp. It also shows good efficacy in simultaneously preventing septicemia, acute hepatopancreatic necrosis, white spot syndrome, and infectious hypodermal and hematopoietic tissue necrosis in shrimp farming.

The invention provides a method for inducing a lyogenic phage based on xanthohumol and application thereof, which are suitable for inducing the lyogenic phage in an escherichia coli host and show a remarkable induction effect. Compared with induction by using 1.5 mu g / ml mitomycin C, the fulvic acid with the final concentration of 1 mu g / ml can induce higher bacteriophage titer; in an in-vivo experiment, a mouse infected with escherichia coli is treated by orally taking xanthohumol, the bacterial load can be remarkably reduced, the phage titer is improved, no obvious toxicity exists, a CCK-8 experiment shows that the survival rate of HepG2 cells given with xanthohumol is remarkably higher than that of HepG2 cells given with mitomycin C group with the same concentration, and xanthohumol shows lower cytotoxicity. The method for inducing the lysogenic bacteriophage based on the xanthohumol is suitable for the fields of bacteriophage therapy, microbiology, microbial ecology and the like, and has a wide application prospect.